Purpose: To explore the use of restriction inhibition assay (RIA) 
INTRODUCTION
Interaction of some anti-tumor agents with DNA has been the subject of intensive research. In this regard, considerable amount of effort has been made to elucidate the molecular basis of action of several drugs such as adriamycin, daunomycin, distamycin-A, mitoxantrone, berberine and palmatine, which are known to bind to DNA. These drugs have good anti-tumor activity and this activity has been correlated to sequence specific binding to DNA. Sequence specificity of these drugs has been attempted using DNA foot printing, in vitro transcription assay, restriction inhibition assay, absorption spectroscopy, fluorescence, circular dichroism spectroscopy, Nuclear Magnetic Resonance (NMR) spectroscopy and X ray crystallography.
DNase foot printing experiments have shown preference for CpG, CpA, TpA sites in DNA with mitoxantrone [1] . Adriamycin and daunomycin have shown affinity for CpA rich sequences [2] . Transcriptional inhibition assay have shown preferences for 5'-(A/T) CA and 5'-(A/T)CG sites on DNA for mitoxantrone [3] and 5'-TCA for adriamycin and GC flanked at 5' by AT sequences for daunomycin [4] . In this context restriction inhibition assay showed more specificity for CA-than GC-rich sequence for adriamycin and more affinity towards GC than AT rich sequence for daunomycin [5] , distamycin-A showed more specificity for AT rich sequence [6] .
The structures of some drugs complexed with specific oligonucleotide have been studied in recent times by X-ray and NMR. The structure of adriamycin complexed with DNA and studied by X-ray [7] and NMR [8] have shown that in these complexes the chromophore is intercalated at CpG, while in the case of daunomycin [9, 10] ], it was noticed that daunomycin intercalates in the d(CpG) and d(TpG) sequences respectively. Structural studies of distamycin A with sequences such as d (CGCGAATTCGCG) 2 [11] and d(CGCAAATTTGCG) 2 using NMR [12] and X-ray [13] respectively, have shown that distamycin-A prefers AT-rich sequence in the minor groove of DNA. In this context, we embarked on experiments to detect the sequence specificity of berberine, palmatine and mitoxantrone whose sequence specific interaction with HindIII (5'-AAGCTT-3'), EcoRI (5'-AAATGC-3') and EcoRV (5'-AATAGC-3') binding sites remained to be explored by restriction inhibition assay. We have also confirmed daunomycin, adriamycin and distamycin-Sequence specificity using Restriction Inhibition Assay (RIA) in conjunction with data from available literature was adopted in which the protocol was standardized the protocol and used for our experimental work.
EXPERIMENTAL

Drugs and chemicals
Adriamycin, daunomycin, distamycin-A, mitoxantrone, berberine and palmatine were purchased from Sigma Aldrich Co. USA. Restriction endonucleases PvuII, HindIII, EcoRI and EcoRV supplied with NEB (10 x) restriction buffer (100 mM Tris-HCl pH 7.5, 1 mM EDTA, 100 mM magnesium acetate, 500 mM potassium acetate) were purchased from New England Biolab, UK. Stock solutions of distamycin-A (100 μM), mitoxantrone (1mM), adriamycin (100 mM), daunomycin (1mM), berberine (100 mM) and palmatine (100 mM) were prepared by dissolving each initially in minimum autoclaved milli-Q water before making up to volume with the same. All solutions were stored at 4 °C.
DNA fragment for restriction inhibition assay (RIA)
The 448 bp fragment was obtained from pBCKS + DNA by the following procedure. The pBCKS + DNA was transformed into E. coli. Cell bearing plasmids were grown and amplified with chloramphenicol (20 μg/ml), and the DNA was isolated and purified by alkaline lysis method [14] . The pBCKS 
Binding studies
The anti-tumor drug-DNA complexes were prepared by preincubating 4 μl (300 ng) of the 448 bp DNA fragment with a range of concentration of the drugs in NEB restriction buffer (1 x) for 30 min at 37 °C. The restriction digestion was carried out by incubating with EcoRI, EcoRV and HindIII respectively for a further 1 h at 37 °C in a final volume of 20 μl. A control setup with the DNA along with each restriction enzyme alone was kept to analyze the results of the restriction inhibition assay. Each digestion was stopped by incubation for 20 min at 65 °C followed by 10 min at 4 °C. A 20 μl of the digestion mixture was added with 5 μl of 6 x DNA loading dye (0.25 % bromophenol blue and 30 % glycerol) and loaded on to 2 % horizontal agarose gel in case of 448 bp DNA fragment which was run in Tris-acetate EDTA buffer (40 mM Tris base, pH 8.0, 18 mM glacial acetic acid and 1 mM EDTA) at 100 V for 2 h. The gel was exposed to 220 nm near UV region spectrum and then the DNA bands were visualized and analyzed for drug-DNA interaction studies.
RESULTS
Binding of distamycin-A, adriamycin and daunomycin to the EcoRI (5'-AAATGC-3') and HindIII (5'-AAGCTT-3') restriction sequence
The results on the detection of binding of Distamycin-A, Adriamycin and Daunomycin to DNA by restriction inhibition assay (RIA).are shown in Fig 1 -3 . We first produced a 448 bp target double stranded DNA fragment consisting of the polylinker region from the pBCKS + plasmid DNA. Second, we allowed distamycin-A, adriamycin and daunomycin to bind to the 448 bp double stranded DNA. In Fig 1, 
Detection of binding of mitoxantrone to the HindIII restriction sequence (5'-AAGCTT-3').
To determine whether binding of mitoxantrone to DNA is detectable by restriction inhibition assay, the experiment shown in Figures 1-3 was repeated using mitoxantone. Figure 4 shows the experiment conducted to demonstrate the binding specificity of mitoxantrone for HindIII restriction sequence (5'-AAGCTT-3'). The drug was studied at different concentrations ranging from 200 to 240 μM. An inhibition of HindIII, in a concentration dependent manner was observed for mitoxantrone and eventually at 220 μM a complete inhibition was seen. The result clearly shows sequence specific interaction of mitoxantrone with HindIII restriction sequence, 5'-AAGCTT-3'. 
Detecting binding of palmatine and berberine to the EcoRI (5'-AAATGC-3') and EcoRV (5'-AATAGC-3') restriction sequences.
The assay was carried to study the binding specificity of berberine and palmatine. Figure  7 shows that under these experimental conditions, berberine and palmatine did not bind to both EcoRI (5'-AAGCTT-3') and EcoRV (5'-AATAGC-3') restriction sequences. The study was carried out using drugs at different concentrations, but even at 2 mM concentration no inhibition of both EcoRI and EcoRV was observed.
DISCUSSION
The principle of RIA assay is based upon the ability of different anti-tumor drugs to inhibit the cleavage activity of restriction endonucleases HindIII, EcoRI and EcoRV. In the gel assays of distamycin-A, adriamycin and daunomycin, a gradual decrease in the intensity of the digested fragment was observed and finally a 100 % inhibition of restriction was observed. It was observed that distamycin inhibits the restriction digestion of EcoRI at 10 μM concentration and shows its sequence specificity towards AT site present in EcoRI. This result is in accordance with earlier studies [6] . They suggested that distamycin binds to AT rich sequences using restriction inhibition assay at 100 μM. It was then further proved by structural studies that distamycin binds to AT base pair by minor groove binding [11] [12] [13] . Adriamycin has been shown to bind to CA with higher affinity than GC rich sequences [2] [3] [4] [5] , using DNase foot printing assay, transcriptional and restriction inhibition assay. In our study adriamycin shows a complete inhibition for HindIII activity at 100 μM concentration and binds to GC rich sequences, which supports the sequence and structural studies done by a few authors using x-ray [7] and NMR [9] methods and this shows that it intercalates between CG base pair. Our results also support daunomycin affinity for GC containing sequence by 100 % inhibition of HindIII activity at 100 µM concentration. This result is in accordance with binding studies of daunomycin by foot printing and restriction inhibition assay [5] , which showed preference of daunomycin for GC base pair flanked by AT base pair. Therefore RIA can provide sequence specificity for these standard drugs used in this study. Structural studies of daunomycin complexed with DNA using x-ray method showed that it intercalates between CG base pair [8] . There are no conclusive reports available regarding structure and conformation of mitoxantrone complexed to DNA. Therefore there is a need for the sequence specificity of mitoxantrone, berberine and palmatine. In this context Fig  4, shows a typical restriction inhibition assay gel for mitoxantrone including a control-the 448 bp DNA fragment without drug. As the concentration of mitoxantrone was increased (lanes 2-6) the intensity of the digested fragments decreased gradually.
Finally, 100 % inhibition in restriction was achieved at 220 µm (lane 4), when compared to the control (lane 1). This result throws an insight on the mitoxantrone specificity for 5'-GC-3'. This result supports the studies by Fox et al [1] and Panousis et al [3] using in vitro transcription assay and DNase foot printing assay, respectively. These assays show sequence specificity towards CG, CA and TA (reading in the 5'-3' direction). Figure  5 shows RIA assay gel of berberine and palmatine with EcoRI and EcoRV. Both palmatine and berberine did not demonstrate binding affinities for either EcoRI or EcoRV recognition sequences irrespective of their concentration. Experimentally standardized binding specificity and the binding concentration of distamycin-A, adriamycin, daunomycin, mitoxantrone, berberine and palmatine with the 448 bp DNA fragment are summarized in Table 1 .
The specificity for each of the drugs was confirmed by performing a negative control experiment using EcoRI as negative control for drugs like mitoxantrone, adriamycin and daunomycin which bind to HindIII binding sites, and HindIII as control for drugs like distamycin-A, berberine and palmatine which are known to bind to either 5'-AT-3' or 5'-TA-3' containing sequences [data not shown]. 
CONCLUSION
The result of our experiment with distamycin-A, adriamycin and daunomycin are similar to those the earlier works. The results obtained with the standards led to successful experimentation with mitoxantrone while the results obtained from restriction inhibition assay of mitoxantrone has shown that binding specificity for 5'-GC-3' is in accordance with that reported by Fox et al [1] and Panousis et al [3] , who showed binding at CG, CA and TA (reading in the 5'-3' direction). Berberine and palmatine which were expected to show binding at 5'-ApT-3'or 5'-TpA-3' did not, even at millimolar concentration. Thus, RIA (restriction inhibition assay) is a sensitive and biologically relevant method to determine the binding concentration and sequence specificity of several anti-tumor drugs. Furthermore, this assay can be useful as a screening protocol for determining both sequence specificity and binding concentration of naturally-occurring and synthetic anti-tumor drug candidates. Additionally, this will be a useful tool to study the mechanism of action of several anti-tumor agents at the molecular level. 
